iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Glenmark Pharmaceuticals Ltd Option Chain

Add as a Preferred Source on Google
2,235.5
(-2.25%)
Jul 17, 2026|09:21:29 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Ol (lots)Call PriceStrike PricePut PriceOl (lots)
2,250-60%₹396.85 -13.86%1,840₹0.8 -20%16,125-2.27%
1,500-42.85%₹363.5 -12.76%1,880₹0.95 0%5,2500%
00%₹401.6 0%1,920₹1 -20%7,500-4.76%
00%₹358.25 0%1,940₹1 11.11%4,500-42.85%
3,7500%₹342 0%1,960₹1.5 0%53,2500%
1,875-37.5%₹259.15 -19.55%1,980₹1.95 0%4,1250%
28,5000%₹311.45 0%2,000₹3 57.89%72,0001.05%
3,0000%₹262.1 0%2,040₹1.85 0%34,1250%
10,5000%₹224.3 0%2,080₹4.3 -55.44%9,75062.5%
13,1250%₹195 0%2,100₹5.5 50.68%85,500-6.17%
--2,120₹7.75 42.2%57,000166.66%
17,6250%₹164.15 0%2,140₹10.15 67.76%45,37589.06%
35,6250%₹137.4 -1.15%2,160₹13.75 85.81%60,37517.51%
36,7500%₹139 0%2,180₹19.15 93.43%48,375-11.64%
2,20,1250.34%₹61.2 -43.01%2,200₹24.65 92.57%3,10,12512.67%
64,875-15.60%₹50.25 -41.53%2,220₹32.2 87.2%1,01,62562.27%
1,04,62522.90%₹40.45 -47.67%2,240₹43.05 90.48%74,25050%
1,33,50085.41%₹31.95 -49.36%2,260₹53.65 77.94%89,250-21.19%
89,6250%₹25 -51.17%2,280₹68.6 79.58%46,500-3.87%
3,77,2501.10%₹19.5 -52.26%2,300₹82.5 71.87%1,35,000-4%
2,80,50012.65%₹14.8 -55.28%2,320₹97.3 62.98%57,000-14.12%
1,41,00046.87%₹11.25 -57.14%2,340--
65,250-21.62%₹8.35 -57.61%2,360--
51,375-2.83%₹6.5 -56.66%2,380--
2,43,750-0.30%₹5.2 -54.78%2,400₹165.05 40.94%27,0005.88%
68,6251.66%₹4 -52.94%2,420--
65,625-0.56%₹2.95 -50.83%2,440--
87,375-0.42%₹2.75 -38.88%2,460₹168.6 0%7500%
14,6250%₹3.8 2.7%2,480₹182.1 0%1,1250%
52,875-10.75%₹1.6 -41.81%2,500--
6,750-5.26%₹2 25%2,520₹254 0%3,7500%
4,1250%₹3.45 0%2,540--
9,375-3.84%₹0.45 -71.87%2,560--
4,50033.33%₹1.2 -52%2,580--
22,875-12.85%₹0.7 -58.82%2,600₹315.8 0%00%
2,250-76%₹0.5 -50%2,640--
3,000300%₹0.75 -88.37%2,680--
1,1250%₹1.45 0%2,720₹417.85 0%45,7500%

Glenmark Pharma.: Related NEWS

Glenmark Pharma Q3 FY26 Profit Rises 16% to ₹403.2 Crore

Revenue from North America increased 24% year on year to ₹970.6 crore, including income from the out licensing of ISB 2001.

31 Jan 2026|02:22 PM
Read More
Top Stocks for Today - 25th September 2025

Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.

25 Sep 2025|06:57 AM
Read More
Top Stocks for Today - 23rd September 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.

23 Sep 2025|07:01 AM
Read More
Glenmark subsidiary gets $700 Million in licensing deal; stock gains

At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.

9 Sep 2025|02:31 PM
Read More
Glenmark Pharma Q1 Net Profit Falls 86% YoY to ₹47 Crore

Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.

18 Aug 2025|01:03 PM
Read More
Top Stocks for Today - 18th August 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.

18 Aug 2025|08:14 AM
Read More
Glenmark Shares Surge 10% After AbbVie Inks Licensing Deal for ISB 2001

The compound is currently in Phase 1B clinical trials, being studied for multiple myeloma, a tough-to-treat form of blood cancer.

11 Jul 2025|09:48 AM
Read More
Top Stocks for Today - 11th July 2025

Here are some of the stocks that may see significant price movement today: Tata Consultancy Services, IREDA, Glenmark Pharma, etc.

11 Jul 2025|07:20 AM
Read More
Top Stocks for Today - 26th May 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.

26 May 2025|06:34 AM
Read More
Glenmark Pharma’s cancer drug receive FDA ‘fast track’ status

ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

6 May 2025|09:31 AM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.